Ciphergen Biosystems, Inc. Names Chief Scientific Officer
FREMONT, Calif., June 19 /PRNewswire-FirstCall/ -- Ciphergen Biosystems, Inc. announced today that Eric T. Fung, M.D., Ph.D. has been promoted to the position of Chief Scientific Officer. In his new position, Dr. Fung will be responsible for setting the strategic direction of Ciphergen's clinical development programs, integrating these programs with the Company's research and development efforts, and helping drive growth strategies in the emerging area of predictive diagnostics. In addition, Dr. Fung will chair the newly formed Scientific Advisory Board.
"Eric has played a key role in developing and managing our diagnostic biomarker pipeline and fostering our collaborations with key accounts such as the Johns Hopkins Medical School, the MD Anderson Cancer Center, and University College London," stated Gail S. Page, President and CEO. "His combination of clinical and scientific experience will help guide us towards commercialization of high value diagnostic tests."
Dr. Fung joined Ciphergen in 2000 as a lead scientist in the newly formed Biomarker Discovery Center(R) laboratories and managed many of Ciphergen's academic and pharmaceutical collaborations. He was most recently Vice President of Clinical and Medical Affairs. Prior to joining Ciphergen, Dr. Fung was a Howard Hughes sponsored researcher at Stanford University. Dr. Fung completed his anatomic pathology internship at Stanford Medical School, and obtained his M.D. and Ph.D. degree in molecular neuroscience from the Johns Hopkins University School of Medicine. He graduated with a BS in biology with honors from the California Institute of Technology. Dr. Fung also currently holds an Adjunct Assistant Professor position in the Department of Pathology at the Johns Hopkins University School of Medicine. Dr. Fung is an author on over 75 publications and abstracts.
About Ciphergen
Ciphergen is dedicated to translating protein biomarkers and panels of biomarkers into protein molecular diagnostic tests that improve patient care. We are also focused on providing collaborative R&D services through our Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at www.ciphergen.com.
Safe Harbor Statement
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding Ciphergen's ability to create and commercialize diagnostic tests that are useful in the prevention of disease. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that Ciphergen may not be able to develop diagnostic tests based on the discoveries of certain biomarkers. Investors should consult Ciphergen's filings with the Securities and Exchange Commission, including its Form 10-K filed March 17, 2006, for further information regarding these and other risks related to the Company's business.
Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.CONTACT: Sue Carruthers, Investor Relations for Ciphergen Biosystems,Inc., +1-510-505-2297
Web site: http://www.ciphergen.com/